{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:40Z","timestamp":1786988140471,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejphar.2026.178857","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:00:14Z","timestamp":1775808014000},"page":"178857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Studying synergistic anticancer effects of repurposed AT1B losartan with antidiabetics metformin, rosiglitazone in triple-negative breast cancer cells"],"prefix":"10.1016","volume":"1022","author":[{"given":"Zakariya","family":"Al-Mashhadani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7543-2807","authenticated-orcid":false,"given":"Yassir Mustafa Kamal","family":"Al Mulla Hummadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wrood S.","family":"AL-khfajy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawfal A.M.","family":"Numan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178857_bib1","article-title":"Drug repurposing for breast cancer therapy: old weapon for new battle","author":"Aggarwal","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejphar.2026.178857_bib2","series-title":"In Silico Drug Design","first-page":"47","article-title":"In silico drug design methods for drug repurposing","author":"Akhoon","year":"2019"},{"issue":"8","key":"10.1016\/j.ejphar.2026.178857_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103654","article-title":"Cinnamic acid enhances vinorelbine-induced cytotoxicity in MDA-MB-231 cells through modulation of PTEN and ATG5 expression","volume":"392","author":"Al Mulla Hummadi","year":"2025","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178857_bib4","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","article-title":"Metastatic and triple-negative breast cancer: challenges and treatment options","volume":"8","author":"Al-Mahmood","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejphar.2026.178857_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/bs.podrm.2015.02.003","article-title":"Losartan: comprehensive profile","volume":"40","author":"Al-Majed","year":"2015","journal-title":"Profiles Drug Subst. Excipients Relat. Methodol."},{"key":"10.1016\/j.ejphar.2026.178857_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2017.00277","article-title":"Screening novel molecular targets of metformin in breast cancer by proteomic approach","volume":"5","author":"Al-Zaidan","year":"2017","journal-title":"Front. Public Health"},{"issue":"8","key":"10.1016\/j.ejphar.2026.178857_bib7","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1078-0432.CCR-22-1630","article-title":"Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, tregs, and FOXP3+ cancer cells in locally advanced pancreatic cancer","volume":"29","author":"Boucher","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178857_bib8","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.18501","article-title":"Macrophage PPAR\u03b3 inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone","volume":"5","author":"Cheng","year":"2016","journal-title":"eLife"},{"issue":"2","key":"10.1016\/j.ejphar.2026.178857_bib9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178857_bib10","author":"Chou"},{"issue":"3","key":"10.1016\/j.ejphar.2026.178857_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2026.178857_bib12","first-page":"1","article-title":"Targeted therapies in triple negative breast cancer: current knowledge and perspectives","volume":"2","author":"Cruz-Lozano","year":"2019","journal-title":"Rec. Stud. Adv. Breast Cancer"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178857_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1535370214546267","article-title":"Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells","volume":"240","author":"de Ara\u00fajo J\u00fanior","year":"2015","journal-title":"Exp. Biol. Med."},{"issue":"10","key":"10.1016\/j.ejphar.2026.178857_bib14","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1940-6207.CAPR-15-0048","article-title":"Effect of metformin on breast ductal carcinoma in situ proliferation in a randomized presurgical trial","volume":"8","author":"DeCensi","year":"2015","journal-title":"Cancer Prev. Res."},{"issue":"24_Suppl. ment","key":"10.1016\/j.ejphar.2026.178857_bib15","article-title":"Abstract PD03-09: metformin induces apoptosis in triple negative breast cancer cells via inhibition of Stat3 activity","volume":"70","author":"Deng","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178857_bib16","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2026.178857_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10911-019-09429-z","article-title":"Metformin and breast cancer: molecular targets","volume":"24","author":"Faria","year":"2019","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.ejphar.2026.178857_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10911-019-09429-z","article-title":"Metformin and breast cancer: molecular targets","volume":"24","author":"Faria","year":"2019","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"issue":"9","key":"10.1016\/j.ejphar.2026.178857_bib19","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","volume":"7","author":"Gandini","year":"2014","journal-title":"Cancer Prev. Res."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178857_bib20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3892\/ol.2022.13258","article-title":"Synergistic inhibition of the growth of MDA-MB-231 cells in triple-negative breast cancer by salinomycin combined with 17-AAG and its mechanism","volume":"23","author":"He","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejphar.2026.178857_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12863-022-01086-2","article-title":"Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy","volume":"23","author":"Hermawan","year":"2022","journal-title":"BMC Genom. Data"},{"issue":"17","key":"10.1016\/j.ejphar.2026.178857_bib22","first-page":"2745","article-title":"Fitting models to biological data using linear and non-linear regression: a practical guide to curve fitting","volume":"24","author":"Holford","year":"2005","journal-title":"Harvey Motulsky and Arthur Christopoulos"},{"key":"10.1016\/j.ejphar.2026.178857_bib23","first-page":"1864","article-title":"Breast cancer molecular subtypes: from TNBC to QNBC","volume":"6","author":"Hon","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178857_bib24","doi-asserted-by":"crossref","first-page":"46652","DOI":"10.18632\/oncotarget.16938","article-title":"Triple negative breast cancer: the kiss of death","volume":"8","author":"Jitariu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2026.178857_bib25","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.2174\/0929867325666180530100332","article-title":"Computational drug repurposing: current trends","volume":"26","author":"Karaman","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejphar.2026.178857_bib26","first-page":"8795","article-title":"Metformin activates AMPK and mTOR to inhibit RANKL-stimulated osteoclast formation","volume":"27","author":"Kim","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178857_bib27","first-page":"89","article-title":"Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer","volume":"13","author":"Li","year":"2023","journal-title":"Bioimpacts"},{"issue":"2","key":"10.1016\/j.ejphar.2026.178857_bib28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clnu.2023.12.005","article-title":"Peroxisome proliferator-activated receptors: a key link between lipid metabolism and cancer progression","volume":"43","author":"Li","year":"2024","journal-title":"Clin. Nutr."},{"issue":"32","key":"10.1016\/j.ejphar.2026.178857_bib29","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.18632\/oncotarget.27694","article-title":"Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models","volume":"11","author":"Mainetti","year":"2020","journal-title":"Oncotarget"},{"issue":"32","key":"10.1016\/j.ejphar.2026.178857_bib30","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.18632\/oncotarget.27694","article-title":"Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models","volume":"11","author":"Mainetti","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2026.178857_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/101705","article-title":"Mechanisms mediating the effects of \u03b3-Tocotrienol when used in combination with PPAR\u03b3 agonists or antagonists on MCF-7 and MDA-MB-231 breast cancer cells","author":"Malaviya","year":"2013","journal-title":"Int. J. Breast Cancer"},{"issue":"11","key":"10.1016\/j.ejphar.2026.178857_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/j.1442-2042.2007.01891.x","article-title":"Editorial comment","volume":"14","author":"Nakagawa","year":"2007","journal-title":"Int. J. Urol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.178857_bib33","first-page":"658","article-title":"Metformin: current knowledge","volume":"19","author":"Nasri","year":"2014","journal-title":"J. Res. Med. Sci."},{"issue":"8_Suppl. ment","key":"10.1016\/j.ejphar.2026.178857_bib34","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1158\/1538-7445.AM10-1078","article-title":"Rosiglitazone inhibits breast cancer growth and proliferation via cyclin D1 inhibition","volume":"70","author":"Oberlick","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178857_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-74277-9","article-title":"Combination of paclitaxel with rosiglitazone induces synergistic cytotoxic effects in ovarian cancer cells","volume":"14","author":"Patel","year":"2024","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178857_bib36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2026.178857_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.14744\/ejmo.2024.61923","article-title":"Effect of losartan on cell proliferation and reactive oxygen species scavenging in gastric cancer cell lines","author":"Raei","year":"2024","journal-title":"Euras. J. Med. Adv."},{"issue":"9","key":"10.1016\/j.ejphar.2026.178857_bib38","first-page":"1","article-title":"Metformin and anti-cancer effects: systematic insights into its therapeutic potential","volume":"18","author":"Ramesh","year":"2024","journal-title":"Oncol. Radiother."},{"issue":"7","key":"10.1016\/j.ejphar.2026.178857_bib39","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41418-022-01022-y","article-title":"Targeting mitochondrial metabolism for precision medicine in cancer","volume":"29","author":"Sainero-Alcolado","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejphar.2026.178857_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114911","article-title":"Metabolic heterogeneity in TNBCs: a potential determinant of therapeutic efficacy of 2-deoxyglucose and metformin combinatory therapy","volume":"164","author":"Samuel","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.ejphar.2026.178857_bib41","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/sj.bjp.0705973","article-title":"GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation","volume":"143","author":"Seargent","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178857_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","article-title":"Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer","volume":"66","author":"Shastry","year":"2022","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.ejphar.2026.178857_bib43","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ccell.2020.05.005","article-title":"Reduction of liver metastasis stiffness improves response to Bevacizumab in metastatic colorectal cancer","volume":"37","author":"Shen","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2026.178857_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/celldisc.2017.10","article-title":"Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation","volume":"3","author":"Shi","year":"2017","journal-title":"Cell Discov."},{"key":"10.1016\/j.ejphar.2026.178857_bib45","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178857_bib46","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/pharmaceutics17050558","article-title":"Metformin-based combination approaches for triple-negative breast cancer","volume":"17","author":"Sirhan","year":"2025","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.ejphar.2026.178857_bib47","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/pharmaceutics17050558","article-title":"Metformin-based combination approaches for triple-negative breast cancer","volume":"17","author":"Sirhan","year":"2025","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.ejphar.2026.178857_bib48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/pharmaceutics17050558","article-title":"Metformin-based combination approaches for triple-negative breast cancer","volume":"17","author":"Sirhan","year":"2025","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.ejphar.2026.178857_bib49","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3390\/biomedicines13061340","article-title":"Dual modulation of adipogenesis and apoptosis by PPARG agonist rosiglitazone and antagonist betulinic acid in 3T3-L1 cells","volume":"13","author":"Sriboonaied","year":"2025","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.ejphar.2026.178857_bib50","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13238-021-00846-7","article-title":"Metabolic reprogramming and epigenetic modifications on the path to cancer","volume":"13","author":"Sun","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejphar.2026.178857_bib51","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs","volume":"116","author":"Timothy","year":"2016","journal-title":"Chem. Rev."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178857_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/ph12040152","article-title":"Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome-review of classical and new compounds: part-I","volume":"12","author":"Vieira","year":"2019","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178857_bib53","first-page":"129","article-title":"Metformin targets glucose metabolism in triple negative breast cancer","volume":"4","author":"Wahdan-Alaswad","year":"2018","journal-title":"J. Oncol. Translat. Res."},{"key":"10.1016\/j.ejphar.2026.178857_bib54","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2026.178857_bib55","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/CMAR.S454960","article-title":"Effects of metformin on JNK signaling pathway and PD-L1 expression in triple negative breast cancer","volume":"16","author":"Wang","year":"2024","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ejphar.2026.178857_bib56","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.2147\/DDDT.S242557","article-title":"The PPAR\u03b3 agonist rosiglitazone enhances the radiosensitivity of human pancreatic cancer cells","volume":"14","author":"Wang","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2026.178857_bib57","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2026.178857_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1017041","article-title":"Ferroptosis and triple-negative breast cancer: potential therapeutic targets","volume":"12","author":"Xu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2026.178857_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1017041","article-title":"Ferroptosis and triple-negative breast cancer: potential therapeutic targets","volume":"12","author":"Xu","year":"2022","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.ejphar.2026.178857_bib60","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1039\/D4NR03054K","article-title":"A responsive cocktail nano-strategy breaking the immune excluded state enhances immunotherapy for triple negative breast cancer","volume":"17","author":"Yang","year":"2025","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178857_bib61","first-page":"30","article-title":"Losartan sensitizes selectively prostate cancer cell to ionizing radiation","volume":"62","author":"Yazdannejat","year":"2016","journal-title":"Cell. Mol. Biol. (Noisy-Le-Grand, France)"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178857_bib62","doi-asserted-by":"crossref","first-page":"52","DOI":"10.33380\/2305-2066-2023-12-1-52-58","article-title":"Cytotoxic effect of 6-Ethyl-Chenodeoxycholic acid and cabazitaxel on PC-3 cells","volume":"12","author":"Zalzala","year":"2023","journal-title":"Drug Develop. Registr."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178857_bib63","first-page":"97","article-title":"Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method","volume":"6","author":"Zhang","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178857_bib64","article-title":"Enhanced therapeutic efficacy of combining losartan and chemo-immunotherapy for triple negative breast cancer","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.178857_bib65","article-title":"Enhanced therapeutic efficacy of combining losartan and chemo-immunotherapy for triple negative breast cancer","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178857_bib66","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/gutjnl-2020-321952","article-title":"ESE3\/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4","volume":"71","author":"Zhou","year":"2022","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.ejphar.2026.178857_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108444","article-title":"Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo","volume":"9","author":"Zhuang","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ejphar.2026.178857_bib68","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.bbagen.2014.01.023","article-title":"The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention","volume":"1840","author":"Zordoky","year":"2014","journal-title":"Biochim. Biophys. Acta Gen. Subj."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:12:46Z","timestamp":1776773566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926003390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":68,"alternative-id":["S0014299926003390"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178857","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Studying synergistic anticancer effects of repurposed AT1B losartan with antidiabetics metformin, rosiglitazone in triple-negative breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178857"}}